MTOR and osteosarcoma: These data revealed that CLTC functioned as an oncogene by regulating the TGF‐beta and AKT/mTOR signaling pathways, and the results encourage the development of CDK4/6 inhibitors and AKT inhibitors for osteosarcoma therapy.